Agendia to Reveal Novel Breast Cancer Outcome Data Identifying Genomic Risk and Treatment Disparities Among Diverse Patient Population at 2025 ASCO Annual Meeting
FLEX Study Highlights Clinical Utility of MammaPrintยฎ and BluePrintยฎ Read More
FLEX Study Highlights Clinical Utility of MammaPrintยฎ and BluePrintยฎ Read More
FLEX Study reaches milestone of 20,000 enrolled patients, providing Read More
Real-world analysis shows BluePrintยฎ identifies chemotherapy-sensitive Basal-type tumorsย among Read More
Poster presentation to highlight new data on MammaPrintยฎ and Read More
IRVINE, CALIF., U.S., and AMSTERDAM, NETHERLANDS โ February 11, Read More
Year-to-Date Achievements Demonstrate Significant Signs of Growth Across All Read More
Gene expression analysis reveals MammaPrintยฎ as the only commercially Read More
New data reinforces findings from MINDACT supporting MammaPrintยฎ in Read More
A secondary analysis of the randomized controlled trial, IDEAL, Read More
New data reinforces MammaPrintยฎ and BluePrintยฎ testsโ expanding clinical Read More